Rate Video

EBMT 2019 | Challenges after CAR T-cell therapy

David Maloney

EBMT 2019

Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia Leukemia Lymphoma CAR-T

Here, David Maloney, MD, PhD, of Fred Hutchinson Cancer Research Center, Seattle, WA, explains the challenges that are faced in the management of patients that undergo CAR T-cell therapy. Dr Maloney was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

CAR T-cell update: what’s new in DLBCL and MM?

David Maloney • 1 Jun 2018

ELARA: tisa-cel shows promise for follicular lymphoma

David Maloney • 15 Dec 2020

Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…

David Maloney et al. • 30 Apr 2022

David Maloney's ASH 2019 CAR-T highlights

David Maloney • 7 Dec 2019

Related Videos

Key challenges of using the intestinal microbiome as a biomarker

CAR T-cell therapy: the importance of LTFU

CD19 CAR T-cell therapy for lymphoma

Michael Schmitt

The future of AML therapy

Andreas Burchert